- HIV prevalence in transgender populations and cisgender men who have sex
- with men in sub-Saharan Africa 2010-2022: a meta-analysis
- 4 Oliver Stevens^{1§}, Rebecca L. Anderson¹, Keith Sabin², Sonia Arias Garcia²,
- 5 Elizabeth Fearon³, Kingsley Manda⁴, Wame Dikobe⁵, Trevor A. Crowell⁶, Leigh
- 6 Tally⁸, Lloyd Mulenga⁹, Neena M. Philip¹⁰, Mathieu Maheu-Giroux¹², Anne
- 7 McIntyre¹¹, Wolfgang Hladik¹¹, Jinkou Zhao¹³, Mary Mahy², Jeffrey W. Eaton^{1,14}
- 9 1 MRC Centre for Global Infectious Disease Analysis, School of Public Health,
- 10 Imperial College London, London, United Kingdom
- 11 2 Data for Impact, The Joint United Nations Program on HIV/AIDS (UNAIDS),
- 12 Geneva, Switzerland

3

- 13 3 University College London, London, United Kingdom
- 14 4 Malawi National Statistics Office, Zomba, Malawi
- 15 5 FHI360, Gaborone, Botswana
- 16 6 U.S. Military HIV Research Program, Walter Reed Army Institute of Research,
- 17 Silver Spring, USA
- 18 7 Henry M. Jackson Foundation for the Advancement of Military Medicine,
- 19 Bethseda, USA
- 20 8 US Centers for Disease Control and Prevention, Lusaka, Zambia
- 21 9 Zambia Ministry of Health, Lusaka, Zambia
- 22 10 ICAP, Columbia University Mailman School of Public Health, New York, New
- 23 York, USA

- 24 11 US Centers for Disease Control and Prevention (CDC), Center for Global Health,
- 25 Division of Global HIV & TB, Atlanta, USA
- 26 12 Department of Epidemiology and Biostatistics, School of Population and Global Health,
- 27 McGill University, Montréal, Canada
- 28 13 The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland
- 29 14 Center for Communicable Disease Dynamics, Department of Epidemiology,
- Harvard T.H. Chan School of Public Health, Boston, MA, USA
- 32 § Corresponding author

- 33 OS: o.stevens@imperial.ac.uk
- 34 RA: Rebecca.anderson21@imperial.ac.uk
- 35 KS: sabink@unaids.org
- 36 SAG: ariasgarcias@unaids.org
- 37 EF: e.fearon@ucl.ac.uk
- 38 KM: mandakingsley@yahoo.com
- 39 WD: wdikobe@fhi360.org
- 40 TC: tcrowell@hivresearch.org
- 41 LT: yml4@cdc.gov
- 42 LM: lloyd.mulenga@moh.gov.zm
- 43 NP: nmp6@cumc.columbia.edu
- 44 MMG: mathieu.maheu-giroux@mcgill.ca
- 45 AM: zat4@cdc.gov
- 46 WH: wfh3@cdc.gov
- 47 JZ: Jinkou.Zhao@theglobalfund.org

48	MM: mahym@unaids.org					
49	JE: Jeffrey.eaton@imperial.ac.uk					
50						
51	Corresponding author:					
52	Oliver Stevens					
53	St. Mary's Hospital Campus Norfolk Place London W2 1PG United Kingdom					
54	o.stevens@imperial.ac.uk					
55						
56	Abstract: 282/350					
57	Main text: 1936/2000					
58	Keywords:					
59	HIV-1; Transgender persons; Homosexuality, Male; Sexual and Gender Minorities;					
60	Africa					
61						
62						
63						

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

Abstract Introduction: The Global AIDS Strategy 2021-2026 calls for equitable and equal access to HIV prevention and treatment programmes for all populations to reduce HIV incidence and end HIV/AIDS as a public health threat by 2030. Transgender populations (TGP), including transmen (TGM) and transwomen (TGW) are populations that have been marginalised and are at high risk of HIV infection in sub-Saharan Africa (SSA). Limited surveillance data on HIV among TGP are available in the region to guide programmatic responses and policymaking. Surveillance data on cisgender men who have sex with men (cis-MSM) are comparatively abundant and may be used to infer TGP HIV prevalence. Methods: Data from key population surveys conducted in SSA between 2010-2022 were identified from existing databases and survey reports. Studies that collected HIV prevalence on both TGP and cis-MSM populations were analysed in a random effect meta-analysis to estimate the ratio of cis-MSM:TGW HIV prevalence. Results: Eighteen studies were identified encompassing 8,052 TGW and 19,492 cis-MSM. TGW HIV prevalence ranged from 0-71.6% and cis-MSM HIV prevalence from 0.14-55.7%. HIV prevalence in TGW was 50% higher than in cis-MSM (prevalence ratio (PR) 1.50 95% CI 1.26-1.79). TGW HIV prevalence was highly correlated with year/province-matched cis-MSM HIV prevalence ($R^2 = 0.62$), but poorly correlated with year/province-matched total population HIV prevalence ($R^2 = 0.1$). Five TGM HIV prevalence estimates were identified ranging from 1-24%. Insufficient TGM data were available to estimate cis-MSM:TGM HIV prevalence ratios.

Conclusion: Transgender women experience a significantly greater HIV burden than cis-MSM in SSA. Bio-behavioural surveys designed and powered to measure determinants of HIV infection, treatment coverage, and risk behaviours among transgender populations, distinct from cis-MSM, will improve understanding of HIV risk and vulnerabilities among TGP and support improved programmes.

Introduction

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

The Global AIDS Strategy 2021-2026 calls for equitable and equal access to HIV prevention and treatment programmes for all populations to reduce HIV incidence and end HIV/AIDS as a public health threat by 2030 [1]. The Strategy has motivated renewed focus to estimate population size, HIV prevalence, ART coverage, and new HIV infections among key populations for all countries in sub-Saharan Africa (SSA) to reduce inequality in the global HIV/AIDS response. Key populations, including transgender and non-binary people, experience a HIV risk environment wherein the combination of high biological HIV risk and sociostructural risk factors result in disproportionate HIV burden [2]–[5]. Societal marginalisation, criminalisation, and stigma have impeded collection of robust HIV surveillance data for key populations in sub-Saharan Africa, particularly for transgender populations [6]–[8]. Global systematic reviews of HIV epidemiology in transgender populations rely on data from high-income countries, Latin America, and South East Asia [4], [5]. Only nine countries in SSA have population size estimates for transgender populations (TGP), twenty countries have surveillance data on HIV prevalence among TGP, and six have ART coverage data [9]. It is uncommon for these data to be disaggregated by gender modality. Though transgender populations are more routinely included in HIV surveillance since the first studies in SSA [10]. [11]. data are insufficient to estimate key HIV epidemic indicators for transgender populations in all sub-Saharan African countries. HIV prevalence data for men who have sex with men (MSM) are more widely available in SSA: over 400 HIV prevalence estimates have been measured since 2010 across 33 of 38 SSA countries [9].

While cis-MSM and transgender women (TGW) have distinct vulnerabilities to HIV [12], [13], studies in SSA indicate that HIV epidemiology in these two populations is linked. TGW most often have male sexual partners, receptive anal sex is common, and qualitative data indicate that some transgender people associate with belonging to the gay community [10], [11], [14]–[16]. Many surveillance studies primarily collecting data among cis-MSM, have also included TGP participants, providing a source of data in the absence of studies explicitly aiming to recruit TGP. This meta-analysis quantified relative HIV prevalence between cis-MSM and TGW and assessed whether there is a consistent relationship to extrapolate MSM HIV prevalence data to estimate TGW HIV prevalence in settings that lack TGP-specific surveillance data.

Methods

We extracted data on HIV prevalence among TGP and cis-MSM between 2010-2022 in sub-Saharan Africa from UNAIDS Global AIDS Monitoring [17], UNAIDS Key Population Atlas [18], The Global Fund to Fight AIDS, TB, and Malaria surveillance database, and US Centers for Disease Control and Prevention key population surveillance databases [9]. Studies were extracted between 2021-2023. Estimates of HIV prevalence for cis-MSM and any transgender population in the same study were considered for inclusion in the meta-analysis. Additional data not published in previous study publications were tabulated and shared by the authors of Fearon et al [16], Keshinro et al. [19], and Malawi 2019/20, Botswana 2017 and Zambia 2021 Biobehavioural Surveys [20]–[22].

HIV prevalence data were pooled and weighted relative to the number tested denominator. Where age-specific HIV prevalence was available, pooled adult prevalence was extracted. Where studies reported HIV prevalence for more than one transgender population, TGW estimates only were included in the meta-analysis. Prevalence ratios (PRs) for HIV prevalence among TGW compared to cis-MSM were calculated separately for Eastern and Southern Africa (ESA) and Western and Central Africa (WCA) regions, and across all of sub-Saharan Africa. Analyses were conducted in R 4.1.2 [23], using the *metafor* package [24]. Cross-sectional estimates of sex-specific total population HIV prevalence at the province level were extracted from UNAIDS subnational HIV estimates for 2020 created using the Naomi model [25]. Naomi is a small-area estimation model used to estimate subnational HIV epidemic indicators for the total population [26]. For each country, province level estimates were projected back in time 2000-2020 parallel to the national-level HIV prevalence trajectory as estimated by the Estimation and Projections Package in Spectrum [27], [28]. Four further estimates of TGW HIV prevalence [14], [29]–[31], ineligible for inclusion in the meta-analysis as they lacked matching cis-MSM HIV prevalence estimates, were included in correlation analysis with total population HIV prevalence. This study received ethical approval from the Imperial College Research and Ethics Committee (#6473559), and as a secondary analysis of anonymised data required neither informed consent from survey participants nor a consent waiver.

Results

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

Nineteen studies with data from nineteen countries (11 in ESA and 8 in WCA) were included in the analysis, encompassing 8,052 TGW and 19,492 cis-MSM (Table 1). Eleven studies were from peer-reviewed literature, and eight were grey literature studies including biobehavioural surveys (BBS) [32] and PLACE studies [33]. The median denominator for TGW HIV prevalence was 89 (IQR 40-195) and for cis-MSM 314 (IQR 134-390). HIV status was ascertained by serological assays in all studies. TGW HIV prevalence ranged from 6.0-69.4% in ESA and 1.9-71.6% in WCA. Cis-MSM HIV prevalence ranged from 1.0-43.7% in ESA and 0.1-55.7% in WCA. Pooling data across sub-Saharan Africa, HIV prevalence in TGW was 50% higher than in cis-MSM (Figure 1; PR 1.50, 95% CI 1.26-1.79). In ESA, prevalence among TGW was 1.49 times higher than cis-MSM (95% CI 1.26-1.75) and in WCA 1.46 times higher (95% CI 0.92-2.32). TGW HIV prevalence was highly correlated with study-matched cis-MSM HIV prevalence (Figure 2: $R^2 = 0.62$) and poorly correlated with UNAIDS province/yearmatched total population HIV prevalence ($R^2 = 0.08$). One-third of studies (6/19) included, or did not specifically exclude, TGM in the sampled transgender population. Of these six studies, five were BBS or PLACE study reports [20], [21], [34]–[36]. One study [35] provided disaggregated TG sample sizes by TG identity, but reported aggregated HIV prevalence across all TGP; and three studies provided neither disaggregated sample sizes nor HIV prevalence [20], [34], [36]. Two studies reported HIV prevalence for non-binary populations [16], [19]. These data were not included in this analysis. Sensitivity analysis excluding the four

studies that reported aggregated HIV prevalence led to a non-significant 6% increase in the relative risk of HIV infection (SSA PR: 1.63, 95% CIs 1.36-1.96).

Five studies reported HIV prevalence estimates for TGM: 10% (4/42) in Benin [31]; 7% (3/44) in Botswana [21]; 4% (2/49) in Uganda [37]; 24% (9/65) in Malawi [38]; and 1% (1/30) in Sierra Leone [35]. Comparison and interpretation of these estimates is challenging as the number of studies and their sample sizes are small and, beyond TGM, there is no population that all four studies tested (Supplementary Table 1). From these limited data, TGM may have a lower risk of HIV infection than TGW.

Discussion

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

HIV prevalence was significantly higher among transgender women than cis-MSM in sub-Saharan Africa, providing further evidence of the HIV vulnerability of TG populations distinct from cis-MSM. Previous studies [4], [5] have identified substantial HIV burden in transgender populations, which this meta-analysis supports both in absolute terms and relative to cis-MSM, already a vulnerable and high-risk population sub-Saharan Africa. Transgender populations are becoming recognised as a key population in sub-Saharan Africa. They are specifically identified in the National Strategic HIV/AIDS Plans of sixteen countries [39], increasing from ten in 2018 [40]. We identified nineteen studies that measured HIV prevalence for TGW and cis-MSM, building on the three African studies included in a recent systematic review [5]. We refrained from reporting pooled estimates of TGW HIV prevalence or relative risk of HIV infection compared to that in the total population as has been presented in previous studies [4], [5]. Firstly, the relative risk of HIV infection in key populations varies with total population HIV prevalence in SSA. Summarising a single relative risk of infection decouples the key population epidemiology in a given country from the HIV epidemic in the total population. In WCA, cis-MSM HIV prevalence can be 100-fold higher than male total population prevalence, while in ESA it may be similar to, or lower than that in the total population [9]. Second, total population HIV prevalence is poorly correlated with cis-MSM HIV prevalence, particularly in WCA where neighbouring countries with similar generalised HIV epidemics can have disparate key population epidemics [9], [41]. Instead, we showed a consistent increased relative risk of HIV infection in TGW compared to cis-MSM. This

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

prevalence ratio may be useful to estimate HIV prevalence among TGW to support programme planning in settings that lack TGP-specific surveillance. These estimates should be viewed as interim estimates until TG-specific HIV surveillance can be conducted. They should not obviate the need for TG surveillance, nor to further discourse that the programmatic needs of TG can be met programmes focused for cis-MSM. We were unable to estimate the relative HIV prevalence between TGM and cis-MSM, though limited data indicated that TGM may have a lower risk of HIV infection than TGW or cis-MSM. Two studies recruited too few transgender men to estimate HIV prevalence [16], [42]. Transgender men remain an understudied population in SSA: the primary focus of only two serogical testing studies to date [31], [37]. Of the six studies in this analysis that did not exclude transgender men, four included recent oral or anal sex with a man as an inclusion criterion. Though data across SSA are limited, they indicate that cis-women are more likely to be partners of transgender men than cis-MSM or other transgender men [21], [37], [43]. Transgender men are likely, therefore, to be excluded from biological surveillance if all transgender populations are associated with the same HIV risk behaviours as cis-MSM. We retained three studies that did not specify which transgender population(s) were recruited in the main analysis [20], [34], [36]. Sexual behaviour data collected in each study indicated that TG participants overwhelmingly reported male sexual partners and receptive anal intercourse. All three studies were recent, published since 2020, and with large sample sizes. Sensitivity analysis indicates that their inclusion had only a marginal impact on the estimated relative risk of HIV infection, and we feel

that their inclusion alongside studies that explicitly recruited TGW is justified. Survey data on gender identity were often ambiguous, necessitating its removal from analysis further reducing sample sizes. Consistently adopting the 'two-step' method, in which survey participants are first asked their assigned sex at birth followed by their gender today, would improve gender identification in key population surveys and enhance comparability across studies [37], [44]. Few measures exist of TG treatment coverage or viral load suppression, and only a subset are laboratory confirmed [9]. While we identified that TGW are at increased risk of HIV infection, it was not possible to estimate ART coverage or access to treatment services either in absolute terms or relative to cis-MSM. This remains a key data gap in monitoring the objectives laid out by the Global AIDS Strategy. Interpretation of this analysis is subject to several limitations. Firstly, we did not differentiate between studies whose primary objective was transgender surveillance [10], [11], [19], [22], [34], [35], [42], [45]–[50], and those that reported transgender participants alongside the primary objective of cis-MSM surveillance [15], [16], [20], [21], [36], [51]. The latter studies may disproportionately recruit TGP who socialise with cis-MSM, leading to sexual behaviour and biological testing data that overstate the similarities between the two populations. Second, insufficient age-specific HIV prevalence data were available to estimate age-adjusted prevalence risk ratios which may lead to underestimated prevalence ratios.

Conclusion

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

Transgender women have 50% higher risk of HIV infection than cis-MSM in SSA and, therefore, TGW and cis-MSM should not be considered as a single risk population. TGW HIV prevalence is highly correlated with cis-MSM prevalence, and cis-MSM HIV prevalence may be used to inform estimates of TGW HIV prevalence in settings that lack TG-specific surveillance. Studies to quantify transgender population size and measure the treatment cascade among transgender people with HIV are a priority to quantify progress towards equitable HIV service access and enable HIV programmes to meet the prevention and treatment needs of transgender populations.

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

Competing interests None **Authors' contributions** OS, KS, MM, and JWE conceptualised the study. KS, SAG, JZ, and AA-Q curated key population survey databases. LF, TC, KM, WD, LM, NP, LT provided additional unpublished data from surveillance studies. OS and RA reviewed primary source documents, deduplicated data, and extracted data. OS analysed the data and wrote the first draft of the manuscript. All authors contributed to interpretation of results and edited the manuscript for intellectual content. All authors read and approved the final version of the manuscript for submission. Acknowledgments and funding This research was supported by UNAIDS, the Bill and Melinda Gates Foundation (OPP1190661), National Institute of Allergy and Infectious Disease of the National Institutes of Health under award number R01-AI136664, and the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union. TC is supported by cooperative agreements between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and the U.S. Department of Defense [W81XWH-11-2-0174, W81XWH-18-2-0040]

The views expressed are those of the authors and should not be construed to represent the positions of the U.S. Army, the Department of Defense, the Department of Health and Human Services, the Henry M. Jackson Foundation for the Advancement of Military Medicine, or the US Centers for Disease Control and Prevention.

Study	Year of publication	Country	Year of data collection	Transgender inclusion criterion	TGW prevalence (%; n/N)	cis-MSM prevalence (%; n/N)	
	2016	Burkina Faso	2013		0% (0/5)	4.5% (1/22)	
Stahlman et al. [11]		Côte d'Ivoire	2015	Assigned male sex at birth and report having had insertive or receptive anal sex with a man in the past 12 months	naving had insertive or receptive anal 23.5% (16/68)		7.3% (4/55)
		Togo	2013	, , , , , , , , , , , , , , , , , , ,	22.2% (2/9)	7.1% (3/42)	
Keshinro et al.	2016			Assigned male sex at birth and report	TGW: 51.5% (123/239)	40.7% (786/1929)	
[19]		Nigeria	2016	having had insertive or receptive anal sex with a man in the past 12 months	Non-binary: 47.6% (111/233) ^Δ		
Botswana MoH [21]	2017	Botswana	2017	Different gender identity to their biological sex at birth	TGW: 50% (6/12) TGM: 6.8% (3/44) ^Δ	14.9% (110/736) ន	
Mozambique MoH [48]	2018	Mozambique	2017	Assigned male at birth	12.7% (15/118)	9.9% (51/517)	
	Côte Ga 2017 Le M Se Es	Burkina Faso	2013		2.8% (3/108)	3.3% (18/552) $\stackrel{\text{ab}}{=}$	
		Côte d'Ivoire	2016		25.5% (76/298)	9.9% (51/517) and de 9.9% (51/517) and de 9.9% (51/517) and de 9.9% (61/766) and de 9.9% (61/	
_		Gambia	2011		50% (2/4)	9% (18/200)	
Poteat et al. [10]		Lesotho	2014	Assigned male sex at birth	59.2% (42/71)	28.6% (130/455)	
[10]		Malawi	2012		16% (12/75)	15.2% (40/263)	
		Senegal	2015		37.2% (74/199)	27.8% (147/528)	
		Eswatini	2011		14.2% (17/120)	18.6% (38/204)	
		Togo	2013		17.6% (9/51)	8.5% (53/626)	
Angola MoH [50]	2018	Angola	2017	Assigned male at birth	9% (8/89)	2% (20/1016) g	
Hakim et al. [49]	2018	Mali	2015	Assigned male sex at birth and report having had insertive or receptive anal sex with a man in the past 6 months	24.3% (9/37)	9% (18/200) 28.6% (130/455) 15.2% (40/263) 27.8% (147/528) 18.6% (38/204) 8.5% (53/626) 2% (20/1016) 9.7% (12/124) 31.3% (47/150) 14.6% (20/137) 17.9% (15/84) 36.9% (90/244)	
Jobson et al. [51]	2018	South Africa	2017	Biologically male, self-identified as having sex with men	57.1% (12/21)	31.3% (47/150)	
		Kenya	2016	Were assigned male sex at birth, ever had sex with a man	25% (8/32)	14.6% (20/137)	
Sandfort et al. [15]	2019	Malawi	2016		31.6% (12/38)	17.9% (15/84)	
		South Africa	2016	Had SOX With a man	57.6% (38/66)	36.9% (90/244)	

medRxiv preprint doi: https://doi.org/10.1101/2023.11.09.23298289; this version posted November 9, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

	me
233)	dRxiv prep (which w
1425)	rint doi: h
4397)	ttps://doi.o
630)	org/10.1101/20 peer review) It is ma
415)	023.11. is the de ava
(522)	09.23298289; this author/funder, who ilable under a CC:
(263)	b has granted BY-NC 4.0 In
1176)	ernational
30)	per 9, 202; a license to license.
1088)	3. The cop o display t
Л)	yright holder for he preprint in per

Fearon et al. [16]	2020	2020 South Africa		Assigned male at birth or current male gender identity. Sex with a man in last 12 months	TGW: 44.6% (20/44) TGM: 50% (1/2) ^Δ Non-binary: 15.4% (2/21) ^Δ	38.6% (90/233)
Malawi MoH [20]	2020	Malawi	Engaged in sexual activities with other men in the past 12 months 13.5% (73/540)		13.5% (73/540)	12.5% (178/1425)
Nigeria MoH [34]	2020	Nigeria	2020	Identifies him/herself as a transsexual and undertakes sexual activity with a man	d undertakes sexual activity with a 18.5% (775/4190)	
Rwema et al. [45]	2020 Rivanda 2018 havind had inspirive or recentive anal		9.4% (10/106)	10.2% (64/630) = 50.2%		
eSwatini MoH [36]	2021	Eswatini	2020	Report have insertive or receptive anal sex with a man in the past 12 months	41.2% (7/17)	20.2% (84/415)
Smith et al. [42]	2021	Kenya	2017	Male sex assignment at birth or male gender identification currently, and having had consensual anal or oral sexual activity with a man in the previous 12 months	gender identification currently, and aving had consensual anal or oral sexual activity with a man in the	
Sullivan et al. [46]	2021	South Africa	2016	Assigned male sex at birth and report having had insertive or receptive anal sex with a man in the past 12 months	59.1% (13/22)	41.8% (110/263) 84.8% (110/263) 41.8% (110/263)
Harris et al. [47]	al. 2022 Zimbabwe 2019 Born biologically male; engaged in anal or oral sex with a man in the past 12 months		27.5% (92/335)	21.1% (248/1176)		
Sierra Leone MoH [35]	20177 Signa I gong 20171 that is diffgrant from his or har say at		4.7% (23/487)	4.2% (18/430)		
Zambia MoH [52]	2023	Zambia	2021	Biologically male at birth and self- reported anal or oral sex with biological male in past 6 months	17% (77/453)	13.5% (147/1088)

Table 1: Studies included in meta-analysis of HIV prevalence in transwomen (TGW) and cis-gendered men who have sex with men (cis-MSM ^Δ Excluded from meta-analysis




Figure 1: Forest plot comparing HIV prevalence ratios in transwomen and cis-gendered men-who-have-sex-with-men. ESA = Eastern and Southern Africa; WCA = Western and Central Africa; SSA = Sub-Saharan Africa.




Figure 2: Comparison of HIV prevalence among transgender women (TGW) and cis-gender menwho-have-sex-with men (cis-MSM) (left) and HIV prevalence among TGW compared to total population 15-49 years (right). The dotted line represents the line of equality is (y = x). Colour of data points represents the UNAIDS region of the study country (ESA = Eastern and Southern Africa; WCA = Western and Central Africa).

			HIV prevalence (%)			
Study	Area	Year	TGM	TGW	cis-MSM	Total population
Benin MoH [31]	Benin	2020	9.5	26.4	7 [43]	0.9
Mujugira et al. [37]	Kampala, Uganda	2020	4.1	20 [14]	12.7 [53]	7.7
Botswana MoH [21]	Botswana	2017	6.8	45.5	14.9	21.4
Malawi MoH [38]	Malawi	2021	23.9	62.3	12.5 [20]	8.1
Sierra Leone [35]	Sierra Leone	2021	1.11	4.36	3.4	1.4

Supplementary Table 1: Estimates of transmen (TGM) HIV prevalence compared with transwomen (TGW), cis-gendered men who have sex with men (cis-MSM), and 15-49 total population both sexes. Estimates in bold are from the same study, and TGW and cis-MSM estimates in italics are the best available comparator estimates from other studies. UNAIDS estimates from Spectrum/Naomi were used for total population HIV prevalence estimates.

References

- [1] United Nations, "End Inequalities. End AIDS. Global AIDS Strategy 2021-2026 | UNAIDS," 2021. https://www.unaids.org/en/resources/documents/2021/2021-2026-global-AIDS-strategy (accessed May 05, 2021).
- [2] T. Poteat, A. Scheim, J. Xavier, S. Reisner, and S. Baral, "Global Epidemiology of HIV Infection and Related Syndemics Affecting Transgender People," *Journal of acquired immune deficiency syndromes (1999)*, vol. 72, no. Suppl 3. Wolters Kluwer Health, pp. S210–S219, Aug. 15, 2016, doi: 10.1097/QAI.0000000000001087.
- [3] M. Singer, N. Bulled, B. Ostrach, and E. Mendenhall, "Syndemics and the biosocial conception of health," *The Lancet*, vol. 389, no. 10072. Lancet Publishing Group, pp. 941–950, Mar. 04, 2017, doi: 10.1016/S0140-6736(17)30003-X.
- [4] S. D. Baral, T. Poteat, S. Strömdahl, A. L. Wirtz, T. E. Guadamuz, and C. Beyrer, "Worldwide burden of HIV in transgender women: A systematic review and meta-analysis," *Lancet Infect. Dis.*, vol. 13, no. 3, pp. 214–222, Mar. 2013, doi: 10.1016/S1473-3099(12)70315-8.
- [5] S. E. Stutterheim, M. Van Dijk, H. Wang, and K. J. Jonas, "The worldwide burden of HIV in transgender individuals: An updated systematic review and meta-analysis," *PLoS ONE*, vol. 16, no. 12 December. Public Library of Science, Dec. 01, 2021, doi: 10.1371/journal.pone.0260063.
- [6] J. Stannah *et al.*, "HIV testing and engagement with the HIV treatment cascade among men who have sex with men in Africa: a systematic review and meta-analysis," *Lancet HIV*, vol. 6, no. 11, pp. e769–e787, Nov. 2019, doi: 10.1016/S2352-3018(19)30239-5.

- [7] L. Degenhardt et al., "Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review," Lancet Glob. Heal., vol. 5, no. 12, pp. e1192–e1207, Dec. 2017, doi: 10.1016/S2214-109X(17)30375-3.
- [8] S. A. Garcia et al., "Availability and quality of surveillance and survey data on HIV prevalence among sex workers, men who have sex with men, people who inject drugs, and transgender women in low- And middle-income countries: Review of available data (2001-2017)," JMIR Public Heal. Surveill., vol. 6, no. 4, Oct. 2020, doi: 10.2196/21688.
- [9] O. Stevens, "Key population size, HIV prevalence, and ART coverage in sub-Saharan Africa: systematic collation and synthesis of survey data," 2022, [Online]. Available: https://www.medrxiv.org/content/10.1101/2022.07.27.22278071v1.
- [10] T. Poteat et al., "HIV prevalence and behavioral and psychosocial factors among transgender women and cisgender men who have sex with men in 8 African countries: A cross-sectional analysis," PLoS Med., 2017, doi: 10.1371/journal.pmed.1002422.
- [11] S. Stahlman et al., "Characterizing the HIV risks and potential pathways to HIV infection among transgender women in Cote d'Ivoire, Togo and Burkina Faso," J. Int. AIDS Soc., vol. 19, no. 3Suppl 2, Jul. 2016, doi: 10.7448/IAS.19.3.20774.
- [12] T. C. Poteat, L. L. A. van der Merwe, J. Sevelius, and J. A. Keatley, "Inclusion as illusion: erasing transgender women in research with MSM," *Journal of the International AIDS Society*, vol. 24, no. 1. John Wiley and Sons Inc, Jan. 01,

- 2021, doi: 10.1002/jia2.25661.
- [13] A. G. Perez-Brumer, C. E. Oldenburg, S. L. Reisner, J. L. Clark, and R. G. Parker, "Towards 'reflexive epidemiology': Conflation of cisgender male and transgender women sex workers and implications for global understandings of HIV prevalence," *Glob. Public Health*, vol. 11, no. 7–8, pp. 849–865, Sep. 2016, doi: 10.1080/17441692.2016.1181193.
- [14] R. King et al., "HIV and transgender women in Kampala, Uganda–Double Jeopardy," Cult. Heal. Sex., vol. 21, no. 6, pp. 727–740, Jun. 2019, doi: 10.1080/13691058.2018.1506155.
- [15] T. G. M. Sandfort et al., "HIV testing and the HIV care continuum among sub-Saharan African men who have sex with men and transgender women screened for participation in HPTN 075," PLoS One, 2019, doi: 10.1371/journal.pone.0217501.
- [16] E. Fearon et al., "HIV testing, care and viral suppression among men who have sex with men and transgender individuals in Johannesburg, South Africa," PLoS One, vol. 15, no. 6, p. e0234384, Jun. 2020, doi: 10.1371/journal.pone.0234384.
- [17] UNAIDS, "Global AIDS Monitoring 2022," 2022.https://www.unaids.org/en/global-aids-monitoring (accessed Feb. 18, 2022).
- [18] UNAIDS, "Key Populations Atlas." https://kpatlas.unaids.org/dashboard (accessed Nov. 27, 2021).
- [19] B. Keshinro *et al.*, "High prevalence of HIV, chlamydia and gonorrhoea among men who have sex with men and transgender women attending trusted community centres in Abuja and Lagos, Nigeria," in *Journal of the International AIDS Society*, 2016, vol. 19, no. 1, doi: 10.7448/IAS.19.1.21270.

- [20] Ministry of Health & National Statistics Office, "Malawi Biological and Behavioural Surveillance Survey 2019-2010," 2020, [Online]. Available: www.nsomalawi.mw.
- [21] Botswana Ministry of Health, "Behavioral and Biological Surveillance Survey of HIV/STI among select high-risk subpopulations in Botswana," 2017.
- [22] Zambia Ministry of Health, "BIOBEHAVIORAL SURVEY AMONG MEN WHO HAVE SEX WITH MEN IN ZAMBIA," no. November, 2021.
- [23] R Core Team, "R: A language and environment for statistical computing." 2021.
- [24] W. Viechtbauer, "Conducting meta-analyses in R with the metafor package.," *J. Stat. Softw.*, 2010.
- [25] UNAIDS, "HIV sub-national estimates viewer," 2021. https://naomi-spectrum.unaids.org/ (accessed May 12, 2022).
- [26] J. W. Eaton *et al.*, "Naomi: a new modelling tool for estimating HIV epidemic indicators at the district level in sub-Saharan Africa," *J. Int. AIDS Soc.*, 2021, doi: 10.1002/jia2.25788.
- [27] J. W. Eaton *et al.*, "The Estimation and Projection Package Age-Sex Model and the r-hybrid model: New tools for estimating HIV incidence trends in sub-Saharan Africa," *AIDS*, vol. 33, no. Suppl 3, pp. S235–S244, Dec. 2019, doi: 10.1097/QAD.0000000000002437.
- [28] J. Stover et al., "Updates to the Spectrum/AIM model for estimating key HIV indicators at national and subnational levels," AIDS, vol. 33, no. Suppl 3, pp. S227–S234, Dec. 2019, doi: 10.1097/QAD.000000000002357.
- [29] Cote d'Ivoire Ministry of Health, "Rapport de l'étude pour l'identification des besoins spécifiques en matière de prévention et prise en charge IST-VIH/SIDA

- chez les personnes transgenres a Abidjan," 2019.
- [30] Mali Ministry of Health, "Analyse de la situation des personnes transgenres au Mali en relation avec l'infection a VIH et la SIDA," 2019.
- [31] Benin Ministry of Health, "Enquete bio-comportementale, cartographie, et estimation de la taille des transgenres au Benin," 2020.
- [32] UNAIDS, FHI 360, WHO, CDC, and PEPFAR, *Biobehavioural Survey Guidelines For Populations At Risk For HIV.* 2017.
- [33] S. Weir, "Priorities for Local AIDS Control Efforts (PLACE)," 2019. [Online].

 Available: https://www.measureevaluation.org/resources/publications/ms-19173/at_download/document.
- [34] Nigeria Ministry of Health, "Integrated Biological & Behavioural Surveillance Survey (IBBSS) among Key Populations in Nigeria," 2020.
- [35] Sierra Leone Ministry of Health, "Integrated Biobehavioural Survey and population size estimation among FSW, MSM, PWID, TG, and PCS in Sierra Leone," 2021.
- [36] eSwatini Ministry of Health, "Integrated biological-behavioural surveillance survey among female sex workers and men who have sex with men in eSwatini," 2021.
- [37] A. Mujugira *et al.*, "You are not a man': a multi-method study of trans stigma and risk of HIV and sexually transmitted infections among trans men in Uganda," *J. Int. AIDS Soc.*, vol. 24, no. 12, Dec. 2021, doi: 10.1002/jia2.25860.
- [38] Malawi Ministry of Health, "HIV risk, access to health services and population size estimate of transgender community in Malawi," 2021.
- [39] J. Sherwood, E. Lankiewicz, E. Castellanos, N. O'Connor, L. Theron, and A. Restar, "Assessing inclusion of trans people in HIV national strategic plans: a

- review of 60 high HIV prevalence countries," *J. Int. AIDS Soc.*, vol. 24, no. 11, p. e25837, Nov. 2021, doi: 10.1002/jia2.25837.
- [40] WHO, "Focus on key populations in national HIV Strategic PLans in the Africa Region," 2018. Accessed: Feb. 18, 2022. [Online]. Available: http://apps.
- [41] P. H. S. Hessou *et al.*, "Comparison of the prevalence rates of HIV infection between men who have sex with men (MSM) and men in the general population in sub-Saharan Africa: A systematic review and meta-analysis," *BMC Public Health*, vol. 19, no. 1, p. 1634, Dec. 2019, doi: 10.1186/s12889-019-8000-x.
- [42] A. D. Smith, J. Kimani, R. Kabuti, P. Weatherburn, E. Fearon, and A. Bourne, "HIV burden and correlates of infection among transfeminine people and cisgender men who have sex with men in Nairobi, Kenya: an observational study," *Lancet HIV*, vol. 8, no. 5, pp. e274–e283, 2021, doi: 10.1016/S2352-3018(20)30310-6.
- [43] Benin Ministry of Health, "Analyse de la situation des transgenres en matiere de l'infection a VIH et le SIDA au Benin," 2017.
- [44] S. L. Reisner *et al.*, "Using a Two-Step Method to Measure Transgender Identity in Latin America/the Caribbean, Portugal, and Spain," *Arch. Sex. Behav.*, vol. 43, no. 8, pp. 1503–1514, Oct. 2014, doi: 10.1007/s10508-014-0314-2.
- [45] J. O. Twahirwa Rwema *et al.*, "HIV infection and engagement in HIV care cascade among men who have sex with men and transgender women in Kigali, Rwanda: a cross sectional study," *J. Int. AIDS Soc.*, vol. 23, no. S6, p. e25604, Oct. 2020, doi: 10.1002/jia2.25604.
- [46] P. S. Sullivan et al., "HIV prevalence and incidence in a cohort of South African

- men and transgender women who have sex with men: the Sibanye Methods for Prevention Packages Programme (MP3) project," *J. Int. AIDS Soc.*, vol. 23, no. S6, Oct. 2020, doi: 10.1002/jia2.25591.
- [47] T. G. Harris *et al.*, "HIV care cascade and associated factors among men who have sex with men, transgender women, and genderqueer individuals in Zimbabwe: findings from a biobehavioural survey using respondent-driven sampling," *Lancet HIV*, vol. 0, no. 0, Feb. 2022, doi: 10.1016/S2352-3018(21)00297-6.
- [48] Mozambique Ministry of Health, "Mapeamento Programático e Prevalência de HIV entre Populações Chave em 5 Províncias de Moçambique: Estudo PLACE 2017," pp. 1–158, 2018.
- [49] A. J. Hakim *et al.*, "An urgent need for HIV testing among men who have sex with men and transgender women in Bamako, Mali: Low awareness of HIV infection and viral suppression among those living with HIV," *PLoS One*, vol. 13, no. 11, pp. 1–14, 2018, doi: 10.1371/journal.pone.0207363.
- [50] Angola Ministry of Health, "Mapeamento Programático e Prevalência de VIH e outras ITS entre Populações Chave de Angola : Estudo PLACE 2017," 2018.
- [51] G. Jobson et al., "Gender identity and HIV risk among men who have sex with men in Cape Town, South Africa," AIDS Care - Psychol. Socio-Medical Asp. AIDS/HIV, vol. 30, no. 11, pp. 1421–1425, 2018, doi: 10.1080/09540121.2018.1465175.
- [52] R. J. Hayes *et al.*, "Effect of Universal Testing and Treatment on HIV Incidence
 HPTN 071 (PopART)," *N. Engl. J. Med.*, vol. 381, no. 3, pp. 207–218, Jul. 2019, doi: 10.1056/NEJMoa1814556.
- [53] W. Hladik et al., "Men Who Have Sex with Men in Kampala, Uganda: Results

from a Bio-Behavioral Respondent Driven Sampling Survey," *AIDS Behav.*, vol. 21, no. 5, pp. 1478–1490, 2017, doi: 10.1007/s10461-016-1535-2.